Irinotecan - ≥99%, high purity , CAS No.97682-44-5, Inhibitor of DNA topoisomerase I

Item Number
I127961
Grouped product items
SKUSizeAvailabilityPrice Qty
I127961-100mg
100mg
In stock
$79.90
I127961-500mg
500mg
In stock
$219.90
I127961-1g
1g
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
$349.90

Basic Description

SynonymsMFCD00866307 | AB00698464-10 | D08086 | (+)-7-ethyl-10-hydroxycamptothecine 10-(1,4'-bipiperidine)-1'-carboxylate | (+)-Irinotecan | CPT-11
Specifications & PurityMoligand™, ≥99%
Biochemical and Physiological Mechanisms(+)-Irinotecan is an isomer of the Topo I inhibitor Irinotecan
Storage TempStore at 2-8°C,Protected from light
Shipped InWet ice
GradeMoligand™
Action TypeINHIBITOR
Mechanism of actionInhibitor of DNA topoisomerase I
Product Description

Irinotecan is a topoisomerase I inhibitor for LoVo cells and HT-29 cells with IC50 of 15.8 μM and 5.17 μM, respectively.

Irinotecan hydrochloride has been used:

in combination with 5-fluorouracil for screening growth inhibitory functionality in MDA-MB-231 breast cancer cells.

in chemosensitivity screening of high-grade appendiceal (HGA) and low-grade appendiceal (LGA) organoids.

as a chemotherapeutic agent in the cytotoxicity studies in combination with heat shock proteins inhibitors (HPSC1) in HT29 colon cancer cells.

Associated Targets(Human)

TOP1 Tclin DNA topoisomerase 1 (0 Activities)
Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)
ACHE Tclin Acetylcholinesterase (1 Activities)
Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)
PDE5A Tclin Phosphodiesterase 5A (5113 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
EGFR Tclin Epidermal growth factor receptor erbB1 (33727 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
CA2 Tclin Carbonic anhydrase II (17698 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
ESR1 Tclin Estrogen receptor alpha (17718 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
HMGCR Tclin HMG-CoA reductase (2475 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
NR3C1 Tclin Glucocorticoid receptor (14987 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
INSR Tclin Insulin receptor (5558 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
PGR Tclin Progesterone receptor (8562 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
ADRB2 Tclin Beta-2 adrenergic receptor (11824 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
CHRM2 Tclin Muscarinic acetylcholine receptor M2 (10671 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
ADRB1 Tclin Beta-1 adrenergic receptor (6630 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
HTR1A Tclin Serotonin 1a (5-HT1a) receptor (14969 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
ADRA2A Tclin Alpha-2a adrenergic receptor (9450 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
AR Tclin Androgen Receptor (11781 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
CHRM1 Tclin Muscarinic acetylcholine receptor M1 (12690 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
TOP1 Tclin DNA topoisomerase I (7553 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
ACE Tclin Angiotensin-converting enzyme (1423 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
DRD2 Tclin Dopamine D2 receptor (23596 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
MAOA Tclin Monoamine oxidase A (11911 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
CNR1 Tclin Cannabinoid CB1 receptor (20913 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
DRD1 Tclin Dopamine D1 receptor (9720 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
DRD4 Tchem Dopamine D4 receptor (7907 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
ACHE Tclin Acetylcholinesterase (18204 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
PTGS1 Tclin Cyclooxygenase-1 (9233 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
SLC6A2 Tclin Norepinephrine transporter (10102 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
HRH2 Tclin Histamine H2 receptor (5428 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
ADRA1D Tclin Alpha-1d adrenergic receptor (4171 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
HTR1B Tclin Serotonin 1b (5-HT1b) receptor (2801 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
HTR2A Tclin Serotonin 2a (5-HT2a) receptor (14758 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
HTR2C Tclin Serotonin 2c (5-HT2c) receptor (11471 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
ADORA1 Tclin Adenosine A1 receptor (17603 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
CALCR Tclin Calcitonin receptor (2215 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
SLC6A4 Tclin Serotonin transporter (12625 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
ADRA1A Tclin Alpha-1a adrenergic receptor (8359 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
PTGS2 Tclin Cyclooxygenase-2 (13999 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
HRH1 Tclin Histamine H1 receptor (7573 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
ADRA1B Tclin Alpha-1b adrenergic receptor (2912 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
OPRM1 Tclin Mu opioid receptor (19785 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
DRD3 Tclin Dopamine D3 receptor (14368 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
AVPR1A Tclin Vasopressin V1a receptor (5412 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
OPRD1 Tclin Delta opioid receptor (15096 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
OPRK1 Tclin Kappa opioid receptor (16155 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
SLC6A3 Tclin Dopamine transporter (10535 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
KCNH2 Tclin HERG (29587 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
HTR4 Tclin Serotonin 4 (5-HT4) receptor (2068 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
ESR2 Tclin Estrogen receptor beta (9272 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
CYSLTR1 Tclin Cysteinyl leukotriene receptor 1 (2118 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
ERBB2 Tclin Receptor protein-tyrosine kinase erbB-2 (7851 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
CHRM4 Tclin Muscarinic acetylcholine receptor M4 (6041 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
CHRM5 Tclin Muscarinic acetylcholine receptor M5 (4677 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Associated Targets(non-human)

Agtr2 Angiotensin II type 2 (AT-2) receptor (803 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
Mc4r Melanocortin receptor 4 (1205 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
Ltc4s Leukotriene C4 synthase (1 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
Sigmar1 Sigma opioid receptor (160 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
Npy1r Neuropeptide Y receptor type 1 (8 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
Cckar Cholecystokinin A receptor (90 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
Abcc1 Multidrug resistance-associated protein 1 (42 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
Abcb1b P-glycoprotein 1 (174 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
Nos2 Nitric oxide synthase, inducible (3573 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
Mapk1 MAP kinase ERK2 (650 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
Hdac6 Histone deacetylase 6 (222 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
Ces1e Liver carboxylesterase 3 (6 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
Mmp9 Matrix metalloproteinase 9 (38 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
Abcb1a P-glycoprotein 3 (492 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
Drosophila melanogaster (359 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
Mus musculus (284745 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
Rattus norvegicus (775804 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
L1210 (27553 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
Colon 26 (524 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
rep Replicase polyprotein 1ab (378 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
Txnrd1 Thioredoxin reductase 1, cytoplasmic (45279 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
Plasma (328 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
Slc22a3 Solute carrier family 22 member 3 (35 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
Abcb1a P-glycoprotein 1 and 3 (MDR1a/MDR1b) (23 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
Glra2 Glycine receptor (1745 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
SARS-CoV-2 (38078 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Names and Identifiers

IUPAC Name [(19S)-10,19-diethyl-19-hydroxy-14,18-dioxo-17-oxa-3,13-diazapentacyclo[11.8.0.02,11.04,9.015,20]henicosa-1(21),2,4(9),5,7,10,15(20)-heptaen-7-yl] 4-piperidin-1-ylpiperidine-1-carboxylate
INCHI InChI=1S/C33H38N4O6/c1-3-22-23-16-21(43-32(40)36-14-10-20(11-15-36)35-12-6-5-7-13-35)8-9-27(23)34-29-24(22)18-37-28(29)17-26-25(30(37)38)19-42-31(39)33(26,41)4-2/h8-9,16-17,20,41H,3-7,10-15,18-19H2,1-2H3/t33-/m0/s1
InChi Key UWKQSNNFCGGAFS-XIFFEERXSA-N
Canonical SMILES CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7
Isomeric SMILES CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)[C@@]4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7
PubChem CID 60838
Molecular Weight 586.68

Certificates

Certificate of Analysis(COA)

Enter Lot Number to search for COA:

Find and download the COA for your product by matching the lot number on the packaging.

8 results found

Lot NumberCertificate TypeDateItem
G2410409Certificate of AnalysisJun 25, 2024 I127961
G2410410Certificate of AnalysisJun 25, 2024 I127961
G2410411Certificate of AnalysisJun 25, 2024 I127961
G2222423Certificate of AnalysisMay 21, 2024 I127961
G2222454Certificate of AnalysisMay 21, 2024 I127961
I2104358Certificate of AnalysisJun 13, 2023 I127961
I2104359Certificate of AnalysisJun 13, 2023 I127961
G2222489Certificate of AnalysisJun 11, 2022 I127961

Chemical and Physical Properties

SolubilitySoluble in DMSO (10 mg/ml at 25 °C), water (<1 mg/ml at 25 °C), and ethanol (<1 mg/ml at 25 °C).
SensitivityLight sensitive

Safety and Hazards(GHS)

Pictogram(s) GHS08,   GHS05,   GHS07
Signal Danger
Hazard Statements

H315:Causes skin irritation

H373:Causes damage to organs through prolonged or repeated exposure

H302:Harmful if swallowed

H318:Causes serious eye damage

H361:Suspected of damaging fertility or the unborn child

Precautionary Statements

P280:Wear protective gloves/protective clothing/eye protection/face protection.

P302+P352:IF ON SKIN: wash with plenty of water.

P321:Specific treatment (see ... on this label).

P405:Store locked up.

P501:Dispose of contents/container to ...

P264:Wash hands [and …] thoroughly after handling.

P260:Do not breathe dust/fume/gas/mist/vapors/spray.

P270:Do not eat, drink or smoke when using this product.

P362+P364:Take off contaminated clothing and wash it before reuse.

P330:Rinse mouth.

P203:Obtain, read and follow all safety instructions before use.

P264+P265:Wash hands [and …] thoroughly after handling. Do not touch eyes.

P301+P317:IF SWALLOWED: Get medical help.

P305+P354+P338:IF IN EYES: Immediately rinse with water for several minutes. Remove contact lenses if present and easy to do. Continue rinsing.

P318:if exposed or concerned, get medical advice.

P317:Get emergency medical help.

P332+P317:If skin irritation occurs: Get medical help.

P319:Get medical help if you feel unwell.

Related Documents

Alternative Products

Citations of This Product

1. Yifan Wu, Xiaoxia Gong, Jianzhong Shen, Kui Zhu.  (2023)  Postantibiotic leukocyte enhancement-mediated reduction of intracellular bacteria by macrophages.  Journal of Advanced Research,      [PMID:37290606] [10.1016/j.jare.2023.05.010]
2. Zhongcheng Yang, Zhijun Cao, Wenxin Wang, Ya Chen, Wanqiu Huang, Shixuan Jiao, Siliang Chen, Lianru Chen, Yuxia Liu, Jianming Mao, Luyong Zhang, Zheng Li.  (2023)  Design, synthesis, and biological evaluation studies of novel carboxylesterase 2 inhibitors for the treatment of irinotecan-induced delayed diarrhea.  BIOORGANIC CHEMISTRY,  138  (106625).  [PMID:37300962] [10.1016/j.bioorg.2023.106625]
3. Lanhong Su, Wen Pan, Xiangxia Li, Xingyu Zhou, Xiaopeng Ma, Yuanzeng Min.  (2023)  Utilizing chemotherapy-induced tumor RNA nanoparticles to improve cancer chemoimmunotherapy.  Acta Biomaterialia,  158  (698).  [PMID:36563773] [10.1016/j.actbio.2022.12.039]
4. Lanhong Su, Yuhao Hao, Rui Li, Wen Pan, Xiaopeng Ma, Jianping Weng, Yuanzeng Min.  (2022)  Red blood cell-based vaccines for ameliorating cancer chemoimmunotherapy.  Acta Biomaterialia,  154  (401).  [PMID:36241013] [10.1016/j.actbio.2022.10.001]
5. Bo Lv, Ruijie Xu, Xinrui Xing, Chuyao Liao, Zunjian Zhang, Pei Zhang, Fengguo Xu.  (2022)  Discovery of Synergistic Drug Combinations for Colorectal Cancer Driven by Tumor Barcode Derived from Metabolomics “Big Data”.  Metabolites,  12  (6): (494).  [PMID:35736427] [10.3390/metabo12060494]
6. Jiao Yang Lu, Fu Rui Zhang, Xue Zhi Ding, Li Qiu Xia, Wei Tao Huang.  (2022)  Natural interface guiding cell: Directly using waste fish scales with rich micro/nano structures for control of cell behaviors.  APPLIED SURFACE SCIENCE,  581  (152348).  [PMID:] [10.1016/j.apsusc.2021.152348]
7. Yue Shi-Jun, Qin Yi-Feng, Kang An, Tao Hui-Juan, Zhou Gui-Sheng, Chen Yan-Yan, Jiang Jian-Qin, Tang Yu-Ping, Duan Jin-Ao.  (2021)  Total Flavonoids of Glycyrrhiza uralensis Alleviates Irinotecan-Induced Colitis via Modification of Gut Microbiota and Fecal Metabolism.  Frontiers in Immunology,  12  (1588).  [PMID:34025639] [10.3389/fimmu.2021.628358]
8. Dou-Dou XU, Xiao-Ying HOU, Ou WANG, Di WANG, Dan-Ting LI, Si-Yuan QIN, Bo LV, Xiao-Min DAI, Zun-Jian ZHANG, Jian-Bo WAN, Feng-Guo XU.  (2021)  A four-component combination derived from Huang-Qin Decoction significantly enhances anticancer activity of irinotecan.  Chinese Journal of Natural Medicines,  19  (364).  [PMID:33941341] [10.1016/S1875-5364(21)60034-1]
9. Ling Duan, Leijiao Deng, Dabin Wang, Shoucheng Ma, Chunmei Li, Da Zhao.  (2017)  Treatment mechanism of matrine in combination with irinotecan for colon cancer.  Oncology Letters,  14  (2): (2300-2304).  [PMID:28781667] [10.3892/ol.2017.6407]

References

1. Staker BL, Hjerrild K, Feese MD, Behnke CA, Burgin Jr AB, Stewart L.  (2002)  The mechanism of topoisomerase I poisoning by a camptothecin analog..  Proc Natl Acad Sci USA,  99  (24): (15387-92).  [PMID:12426403] [10.1021/op500134e]
2. Pommier Y, Redon C, Rao VA, Seiler JA, Sordet O, Takemura H, Antony S, Meng L, Liao Z, Kohlhagen G et al..  (2003)  Repair of and checkpoint response to topoisomerase I-mediated DNA damage..  Mutat Res,  532  (1-2): (173-203).  [PMID:14643436] [10.1021/op500134e]
3. Chrencik JE, Staker BL, Burgin AB, Pourquier P, Pommier Y, Stewart L, Redinbo MR.  (2004)  Mechanisms of camptothecin resistance by human topoisomerase I mutations..  J Mol Biol,  339  (4): (773-84).  [PMID:15165849] [10.1021/op500134e]
4. Tsuruo T, Matsuzaki T, Matsushita M, Saito H, Yokokura T.  (1988)  Antitumor effect of CPT-11, a new derivative of camptothecin, against pleiotropic drug-resistant tumors in vitro and in vivo..  Cancer Chemother Pharmacol,  21  (1): (71-4).  [PMID:3342468] [10.1021/op500134e]
5. Matsuzaki T, Yokokura T, Mutai M, Tsuruo T.  (1988)  Inhibition of spontaneous and experimental metastasis by a new derivative of camptothecin, CPT-11, in mice..  Cancer Chemother Pharmacol,  21  (4): (308-12).  [PMID:3370738] [10.1021/op500134e]
6. Kunimoto T, Nitta K, Tanaka T, Uehara N, Baba H, Takeuchi M, Yokokura T, Sawada S, Miyasaka T, Mutai M.  (1987)  Antitumor activity of 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxy-camptothec in, a novel water-soluble derivative of camptothecin, against murine tumors..  Cancer Res,  47  (22): (5944-7).  [PMID:3664496] [10.1021/op500134e]
7. Yifan Wu, Xiaoxia Gong, Jianzhong Shen, Kui Zhu.  (2023)  Postantibiotic leukocyte enhancement-mediated reduction of intracellular bacteria by macrophages.  Journal of Advanced Research,      [PMID:37290606] [10.1016/j.jare.2023.05.010]
8. Zhongcheng Yang, Zhijun Cao, Wenxin Wang, Ya Chen, Wanqiu Huang, Shixuan Jiao, Siliang Chen, Lianru Chen, Yuxia Liu, Jianming Mao, Luyong Zhang, Zheng Li.  (2023)  Design, synthesis, and biological evaluation studies of novel carboxylesterase 2 inhibitors for the treatment of irinotecan-induced delayed diarrhea.  BIOORGANIC CHEMISTRY,  138  (106625).  [PMID:37300962] [10.1016/j.bioorg.2023.106625]
9. Lanhong Su, Wen Pan, Xiangxia Li, Xingyu Zhou, Xiaopeng Ma, Yuanzeng Min.  (2023)  Utilizing chemotherapy-induced tumor RNA nanoparticles to improve cancer chemoimmunotherapy.  Acta Biomaterialia,  158  (698).  [PMID:36563773] [10.1016/j.actbio.2022.12.039]
10. Lanhong Su, Yuhao Hao, Rui Li, Wen Pan, Xiaopeng Ma, Jianping Weng, Yuanzeng Min.  (2022)  Red blood cell-based vaccines for ameliorating cancer chemoimmunotherapy.  Acta Biomaterialia,  154  (401).  [PMID:36241013] [10.1016/j.actbio.2022.10.001]
11. Bo Lv, Ruijie Xu, Xinrui Xing, Chuyao Liao, Zunjian Zhang, Pei Zhang, Fengguo Xu.  (2022)  Discovery of Synergistic Drug Combinations for Colorectal Cancer Driven by Tumor Barcode Derived from Metabolomics “Big Data”.  Metabolites,  12  (6): (494).  [PMID:35736427] [10.3390/metabo12060494]
12. Jiao Yang Lu, Fu Rui Zhang, Xue Zhi Ding, Li Qiu Xia, Wei Tao Huang.  (2022)  Natural interface guiding cell: Directly using waste fish scales with rich micro/nano structures for control of cell behaviors.  APPLIED SURFACE SCIENCE,  581  (152348).  [PMID:] [10.1016/j.apsusc.2021.152348]
13. Yue Shi-Jun, Qin Yi-Feng, Kang An, Tao Hui-Juan, Zhou Gui-Sheng, Chen Yan-Yan, Jiang Jian-Qin, Tang Yu-Ping, Duan Jin-Ao.  (2021)  Total Flavonoids of Glycyrrhiza uralensis Alleviates Irinotecan-Induced Colitis via Modification of Gut Microbiota and Fecal Metabolism.  Frontiers in Immunology,  12  (1588).  [PMID:34025639] [10.3389/fimmu.2021.628358]
14. Dou-Dou XU, Xiao-Ying HOU, Ou WANG, Di WANG, Dan-Ting LI, Si-Yuan QIN, Bo LV, Xiao-Min DAI, Zun-Jian ZHANG, Jian-Bo WAN, Feng-Guo XU.  (2021)  A four-component combination derived from Huang-Qin Decoction significantly enhances anticancer activity of irinotecan.  Chinese Journal of Natural Medicines,  19  (364).  [PMID:33941341] [10.1016/S1875-5364(21)60034-1]
15. Ling Duan, Leijiao Deng, Dabin Wang, Shoucheng Ma, Chunmei Li, Da Zhao.  (2017)  Treatment mechanism of matrine in combination with irinotecan for colon cancer.  Oncology Letters,  14  (2): (2300-2304).  [PMID:28781667] [10.3892/ol.2017.6407]

Solution Calculators